Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

587 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TERT promoter mutations in primary central nervous system lymphoma are associated with spatial distribution in the splenium.
Bruno A, Alentorn A, Daniau M, Labussière M, Rahimian A, Tabouret E, Polivka M, Jouvet A, Adam C, Figarella-Branger D, Chrétien F, Eimer S, Houillier C, Soussain C, Mokhtari K, Hoang-Xuan K. Bruno A, et al. Acta Neuropathol. 2015 Sep;130(3):439-40. doi: 10.1007/s00401-015-1461-9. Epub 2015 Jul 21. Acta Neuropathol. 2015. PMID: 26195323 No abstract available.
Clinical epidemiology for childhood primary central nervous system tumors.
Bauchet L, Rigau V, Mathieu-Daudé H, Fabbro-Peray P, Palenzuela G, Figarella-Branger D, Moritz J, Puget S, Bauchet F, Pallusseau L, Duffau H, Coubes P, Trétarre B, Labrousse F, Dhellemmes P; Société Française de Neurochirurgie Pédiatrique; Société Française de Neurochirurgie; Société Française de Neuropathologie; Association des Neuro-Oncologues d'Expression Française. Bauchet L, et al. J Neurooncol. 2009 Mar;92(1):87-98. doi: 10.1007/s11060-008-9740-0. Epub 2008 Nov 20. J Neurooncol. 2009. PMID: 19020806
Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis.
Metellus P, Coulibaly B, Colin C, de Paula AM, Vasiljevic A, Taieb D, Barlier A, Boisselier B, Mokhtari K, Wang XW, Loundou A, Chapon F, Pineau S, Ouafik L, Chinot O, Figarella-Branger D. Metellus P, et al. Acta Neuropathol. 2010 Dec;120(6):719-29. doi: 10.1007/s00401-010-0777-8. Epub 2010 Nov 16. Acta Neuropathol. 2010. PMID: 21080178
French brain tumor database: 5-year histological results on 25 756 cases.
Rigau V, Zouaoui S, Mathieu-Daudé H, Darlix A, Maran A, Trétarre B, Bessaoud F, Bauchet F, Attaoua R, Fabbro-Peray P, Fabbro M, Kerr C, Taillandier L, Duffau H, Figarella-Branger D, Costes V, Bauchet L; Société Française de Neuropathologie (SFNP), Société Française de Neurochirurgie (SFNC); Club de Neuro-Oncologie of the Société Française de Neurochirurgie (CNO-SFNC); Association des Neuro-Oncologues d’Expression Française (ANOCEF). Rigau V, et al. Brain Pathol. 2011 Nov;21(6):633-44. doi: 10.1111/j.1750-3639.2011.00491.x. Epub 2011 Jul 25. Brain Pathol. 2011. PMID: 21554472 Free PMC article.
Comparative assessment of 5 methods (methylation-specific polymerase chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients.
Quillien V, Lavenu A, Karayan-Tapon L, Carpentier C, Labussière M, Lesimple T, Chinot O, Wager M, Honnorat J, Saikali S, Fina F, Sanson M, Figarella-Branger D. Quillien V, et al. Cancer. 2012 Sep 1;118(17):4201-11. doi: 10.1002/cncr.27392. Epub 2012 Jan 31. Cancer. 2012. PMID: 22294349 Free article.
587 results